Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation
Detection Principle
ImmunoAssay-Antibody
Testing Method Category
Other Immuno assay
Testing Method
ARCHITECT SARS-CoV-2 N IgG Immunoassay (Abbot, Illinois, U.S.A), LIAISON SARS-CoV-2 S1/S2 IgG (Diasorin, Saluggia,Italy), Elecsys N Anti-SARS-CoV-2 (Roche, Mannheim, Germany), VIDAS SARS-COV-2 RBD IgG (BioMérieux, Marcy-l'Etoile, France), Siemens SARS-CoV-2 RBD Total (COV2T) (Siemens, NY, USA), Access SARS-CoV-2 RBD IgG assay (Beckman-Coulter, CA, U.S.A.) and in house RBD ELISA test
Reported Performance
Specificity: 99.5% (Abbott), 98.7% (Diasorin), 98.9% (VIDAS IgG), 100% (Roche and Beckman), 97.7% (ELISA), 98.8% (siemens) ; Sensitivity: 84.7% (Abbott), 82.4% (Diasorin), 89.3% (VIDAS IgG), 89% (Roche), 89.4% (ELISA), 81.5% (Beckman), 85.9% (Siemens)
Sample Size
3089 samples
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements